546 related articles for article (PubMed ID: 18257856)
1. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma.
Hutterer GC; Karakiewicz PI; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Serretta V; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Perrotte P; Lotan Y; Marberger MJ; Shariat SF
BJU Int; 2008 Mar; 101(5):561-5. PubMed ID: 18257856
[TBL] [Abstract][Full Text] [Related]
2. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology.
Shariat SF; Casella R; Wians FH; Ashfaq R; Balko J; Sulser T; Gasser TC; Sagalowsky AI
Eur Urol; 2004 Mar; 45(3):304-13; author reply 313. PubMed ID: 15036675
[TBL] [Abstract][Full Text] [Related]
3. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
7. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
8. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
[TBL] [Abstract][Full Text] [Related]
9. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
10. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder.
Karakiewicz PI; Benayoun S; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Marberger MJ; Shariat SF
BJU Int; 2006 May; 97(5):997-1001. PubMed ID: 16542342
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
12. Could nuclear matrix protein 22 (NMP22) play a role with urine cytology in screening for bladder cancer?--experience at Kuwait University.
Kapila K; Kehinde EO; Anim JT; Mojiminiyi OA; Vinsu A; George SS; Al-Maghrebi M; Al-Mulla F
Cytopathology; 2008 Dec; 19(6):369-74. PubMed ID: 18631356
[TBL] [Abstract][Full Text] [Related]
13. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
[TBL] [Abstract][Full Text] [Related]
14. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent bladder cancer: NMP22 test or urine cytology?
Hosseini J; Golshan AR; Mazloomfard MM; Mehrsai AR; Zargar MA; Ayati M; Shakeri S; Jasemi M; Kabiri M
Urol J; 2012; 9(1):367-72. PubMed ID: 22395834
[TBL] [Abstract][Full Text] [Related]
16. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
17. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
Jamshidian H; Kor K; Djalali M
Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
[TBL] [Abstract][Full Text] [Related]
18. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
19. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of usefulness of urinary nuclear matrix protein 22 (NMP22) in the detection of urothelial transitional cell carcinoma].
Miyoshi Y; Matsuzaki J; Miura T
Hinyokika Kiyo; 2001 Jun; 47(6):379-83. PubMed ID: 11496392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
